ClinicalTrials.gg
Active, not recruitingNCT04540497Updated Dec 11, 2025Results posted

A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease

A Phase 3 interventional study of Inebilizumab and Placebo in IgG4 Related Disease, sponsored by Amgen. Active, not recruiting at 72 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-11.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 40 studies in Immunoglobulin G4-Related Disease with a site in China — 25 open to participants now, 28 under way, 5 of them phase 3. Immunoglobulin G4-Related Disease · China.

Enrollment
5th of 36
135 · median 59
Started
2020
with 2 others
Phase 3
4 of 40
2 open now
Primary completion
2024-04
later than 0 of 27 live
Registered
10th of 40
by date
Lead sponsor
2 of 40
Amgen

Among the 40 studies in Immunoglobulin G4-Related Disease with a site in China, this one is the 5th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2020, is one of 4 in phase 3, reaches primary completion later than 0 of the 27 other live ones, and was the 10th registered.

Immunoglobulin G4-Related Disease

72 studies on the registry are indexed under Immunoglobulin G4-Related Disease; 40 are open to participants now.

Browse Immunoglobulin G4-Related Disease studies →

Open to participants now

25 of the 40 studies in Immunoglobulin G4-Related Disease with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 28 Immunoglobulin G4-Related Disease studies recruiting now, 12 (43%) set no upper age limit and 13 (46%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Immunoglobulin G4-Related Disease with a site in China, or all of them as a file.
02

Study summary

This study aims to evaluate the efficacy and safety of inebilizumab for the prevention of flare of Immunoglobulin G4-related disease (IgG4-RD).

Read the detailed description

After a screening period of up to 28 days, subjects with IgG4-RD at high risk of flare due to multi-organ disease and recent active disease will be randomized in a 1:1 ratio to receive intravenous (IV) inebilizumab or placebo after premedication during the 52-week randomized control period (RCP). All subjects will receive an initial tapering dose of glucocorticoids (GCs) to complete treatment of their active disease. Flares occurring during study will be treated. The primary endpoint is time to a first adjudication committee-determined, investigator-treated disease flare during the RCP. The primary analysis will be conducted when the last subject completes the RCP visit or discontinues the RCP. This study includes an optional 3-year open-label treatment period. The study also includes a Safety Follow-up Period (SFUP) of up to 730 days for all participants. The expected duration of each subject's participation in this study is up to 400 days (screening and RCP), plus up to 1095 days for eligible subjects who enroll in the optional open label period (OLP), and up to 730 days for the SFUP, for a total maximum duration of up to 2273 days (screening, RCP, interval between RCP and OLP, OLP, and FSUP).

Study acquired from Horizon in 2024.

03

Conditions studied

  • IgG4 Related Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male or female adults, ≥ 18 years of age at time of .
  2. Clinical diagnosis of IgG4-RD.
  3. Fulfillment of the 2019 ACR/EULAR classification criteria.
  4. Experiencing (or recently experienced) an IgG4-RD flare that requires initiation or continuation of (GC) treatment at the time of informed consent.
  5. IgG4-RD affecting at least 2 organs/sites at any time in the course of IgG4-RD
  6. Non-sterilized male subjects who are sexually active with a female partner of must use a condom with spermicide from Day 1 through to the end of the study and must agree to continue using such precautions for at least 6 months after the final dose of IP. Females of childbearing potential who are sexually active with a non-sterilized male partner must use a highly effective method of

Key Exclusion Criteria:

  1. History of solid organ or cell-based transplantation or known immunodeficiency disorder.
  2. Active or history of malignancy that was active within the last 10 years (some specific situations for cervical, skin or prostate cancer are acceptable).
  3. Receipt of any biologic B cell-depleting therapy or non-depleting B-cell-directed therapy in the 6 months prior to screening.
  4. Receipt of non-biologic DMARD or agent other than GCs within 4 weeks prior to screening.
  5. Active tuberculosis or high risk for tuberculosis; infection in absence of curative treatment; evidence of infection.
  6. Receipt of or live therapeutic infectious agent within 2 weeks prior to screening.
  7. Estimated \< 30 mL/min/1.73 m\^2.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    VIB0551

    Inebilizumab administered as an IV infusion.

    Drug: Inebilizumab

  • Placebo comparator
    Placebo

    Placebo administered as an IV infusion.

    Other: Placebo

Interventions

  • Inebilizumab is a monoclonal antibody that depletes B cells.

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. RCP: Time to Disease Flare

    Time to disease flare was defined as the number of days from Day 1 (dosing) to the date of the first treated and Adjudication Committee (AC)-determined IgG4-RD flare within the 52-week RCP. The date of disease flare was determined by the initiation of any flare treatment, including new or increased glucocorticoid (GC) treatment, other immunotherapy, or an interventional procedure, as deemed necessary by the Investigator to address the flare. Kaplan-Meier (KM) method was used to estimate the median time to flare, and 95% confidence interval (CI).

    Time frame: Up to Week 52

Secondary outcomes

  1. RCP: Annualized Rate of Treated and AC-Determined Flares During the RCP

    The annualized rate of treated and AC-determined flares during the 52-week RCP was calculated by dividing the total number of treated and AC-determined flares by the total time at risk (in years) for all participants. This measure reflected the frequency of disease flares per person per year during the RCP.

    Time frame: Week 52

  2. RCP: Percentage of Participants Achieving Flare-free, Treatment-free Complete Remission at Week 52

    Flare-free, treatment-free complete remission at Week 52 was defined as the absence of evident disease activity at Week 52, no AC-determined flare during the RCP, and no treatment for flare or disease control, except for the required 8-week glucocorticoid taper. Lack of evident disease activity was determined by either a score of 0 on the IgG4-RD Responder Index (score range: 0-4, with lower scores indicating better disease control) or an investigator's assessment that no disease activity was present based on physical, laboratory, pathology, or other evidence.

    Time frame: Week 52

  3. RCP: Percentage of Participants Achieving Flare-free, Corticosteroid-free Complete Remission at Week 52

    Flare-free, corticosteroid-free complete remission at Week 52 was defined as the absence of evident disease activity at Week 52, no AC-determined flare during the RCP, and no corticosteroid treatment for flare or disease control, except for the required 8-week glucocorticoid taper. Lack of evident disease activity was determined by either a score of 0 on the IgG4-RD Responder Index (score range: 0-4, with lower scores indicating better disease control) or an investigator's assessment that no disease activity was present based on physical, laboratory, pathology, or other evidence.

    Time frame: Week 52

  4. Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) During the RCP

    An adverse event (AE) referred to any untoward medical occurrence in a clinical study participant, regardless of a causal relationship with the study treatment. TEAEs included any event occurring after the participant received the study treatment. Clinically significant changes in vital signs, electrocardiograms, and laboratory tests recorded after treatment administration were documented as TEAEs. Serious AEs (SAEs) were untoward medical occurrences after the first dose, irrespective of a causal link to the study treatment, that led to death, were life-threatening, required hospitalization or its prolongation, caused significant disability, resulted in congenital anomalies, or were considered other medically important events. AEs were graded (Grade 3: severe; Grade 4: life-threatening; Grade 5: death) using the Common Terminology Criteria for Adverse Events \[CTCAE\]).

    Time frame: Up to Week 52

  5. Number of Participants Who Experienced TEAEs During the OLP

    An AE referred to any untoward medical occurrence in a clinical study participant, regardless of a causal relationship with the study treatment. TEAEs included any event occurring after the participant received the study treatment. Clinically significant changes in vital signs, electrocardiograms, and laboratory tests recorded after treatment administration were documented as TEAEs. SAEs were untoward medical occurrences after the first dose, irrespective of a causal link to the study treatment, that led to death, were life-threatening, required hospitalization or its prolongation, caused significant disability, resulted in congenital anomalies, or were considered other medically important events. AEs were graded (Grade 3: severe; Grade 4: life-threatening; Grade 5: death) using the CTCAE).

    Time frame: From the first dose of investigational product in OLP to the end of OLP or cutoff date; median (min, max) duration was 51.6 (0.1, 108.3) weeks.

  6. RCP: Number of Participants With Anti-drug Antibodies (ADA) to Inebilizumab by Week 52

    Incidence was the proportion of the participants with ADA positive post-baseline only or boosted their preexisting ADA (at least 4-fold over the baseline titer) during the study period. Baseline was defined as the last valid value on or before the first dose of RCP.

    Time frame: Baseline to Week 52

  7. RCP: Time to Initiation of First Treatment for New or Worsening Disease Activity Within the RCP

    Time to initiation of the first treatment (medication or procedure) for new or worsening disease activity, as determined by the investigator, within the RCP, was measured from day 1 (dosing) to the date the first treatment was administered. It Included any treatment initiated by the investigator for disease activity, regardless of the AC determination of flare. KM method was used to estimate the median time to the initiation of first treatment or worsening of disease activity, and 95% CI.

    Time frame: Week 52

  8. RCP: Annualized Flare Rate for AC-Determined IgG4-RD Flares at Week 52

    The annualized flare rate for AC-determined IgG4-RD flares, whether or not treated, during the RCP was calculated by dividing the total number of AC-determined flares by the total time at risk (in years) for all participants. This measure reflected the frequency of IgG4-RD flares, irrespective of treatment, per participant per year during the study period.

    Time frame: Week 52

  9. RCP: Cumulative Glucocorticoid (GC) Use for IgG4-RD Disease Control by Week 52

    GC use was calculated as the cumulative glucocorticoid dose (in milligrams) taken for the purpose of IgG4-RD disease control during the RCP. This measure accounted for all GC treatments administered to participants to manage disease activity throughout the study period.

    Time frame: Week 52

07

Results

Posted Jun 25, 2025

Participant flow

Participants affected by immunoglobulin G4-related disease (IgG4-RD) were recruited across 46 sites in Argentina, Australia, Canada, China, France, Germany, Israel, Italy, Japan, Mexico, Netherlands, Poland, Spain, Turkey, the United Kingdom and the United States, between December 2020 and February 2024 which was the safety data cutoff date.

Participant flow — Overall Study
MilestoneRCP: Placebo/OLP: Inebilizumab 300 mgRCP: Inebilizumab 300 mg/OLP: Inebilizumab 300 mg
Started6768
Started optional olp4953
Completed6364
Not completed44
Withdrew: Adverse event02
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject11
Withdrew: Miscellaneous21

Outcome measures

PrimaryRCP: Time to Disease Flare

Time to disease flare was defined as the number of days from Day 1 (dosing) to the date of the first treated and Adjudication Committee (AC)-determined IgG4-RD flare within the 52-week RCP. The date of disease flare was determined by the initiation of any flare treatment, including new or increased glucocorticoid (GC) treatment, other immunotherapy, or an interventional procedure, as deemed necessary by the Investigator to address the flare. Kaplan-Meier (KM) method was used to estimate the median time to flare, and 95% confidence interval (CI).

Time frame:
Up to Week 52
Reported as:
Median · Days
RCP: Time to Disease Flare
DaysPlaceboInebilizumab 300 mg
RCP: Time to Disease Flare246.0 (191.0 to NA)NA (371.0 to NA)
Statistical analysis
  • Placebo vs Inebilizumab 300 mg · Hazard ratio (hr): 0.13 · 95% CI 0.06 to 0.28Inebilizumab versus placebo
SecondaryRCP: Annualized Rate of Treated and AC-Determined Flares During the RCP

The annualized rate of treated and AC-determined flares during the 52-week RCP was calculated by dividing the total number of treated and AC-determined flares by the total time at risk (in years) for all participants. This measure reflected the frequency of disease flares per person per year during the RCP.

Time frame:
Week 52
Reported as:
Number · Flares per person per year
RCP: Annualized Rate of Treated and AC-Determined Flares During the RCP
Flares per person per yearPlaceboInebilizumab 300 mg
RCP: Annualized Rate of Treated and AC-Determined Flares During the RCP0.71 (0.53 to 0.94)0.10 (0.05 to 0.21)
SecondaryRCP: Percentage of Participants Achieving Flare-free, Treatment-free Complete Remission at Week 52

Flare-free, treatment-free complete remission at Week 52 was defined as the absence of evident disease activity at Week 52, no AC-determined flare during the RCP, and no treatment for flare or disease control, except for the required 8-week glucocorticoid taper. Lack of evident disease activity was determined by either a score of 0 on the IgG4-RD Responder Index (score range: 0-4, with lower scores indicating better disease control) or an investigator's assessment that no disease activity was present based on physical, laboratory, pathology, or other evidence.

Time frame:
Week 52
Reported as:
Count of participants · Participants
RCP: Percentage of Participants Achieving Flare-free, Treatment-free Complete Remission at Week 52
ParticipantsPlaceboInebilizumab 300 mg
RCP: Percentage of Participants Achieving Flare-free, Treatment-free Complete Remission at Week 521539
SecondaryRCP: Percentage of Participants Achieving Flare-free, Corticosteroid-free Complete Remission at Week 52

Flare-free, corticosteroid-free complete remission at Week 52 was defined as the absence of evident disease activity at Week 52, no AC-determined flare during the RCP, and no corticosteroid treatment for flare or disease control, except for the required 8-week glucocorticoid taper. Lack of evident disease activity was determined by either a score of 0 on the IgG4-RD Responder Index (score range: 0-4, with lower scores indicating better disease control) or an investigator's assessment that no disease activity was present based on physical, laboratory, pathology, or other evidence.

Time frame:
Week 52
Reported as:
Count of participants · Participants
RCP: Percentage of Participants Achieving Flare-free, Corticosteroid-free Complete Remission at Week 52
ParticipantsPlaceboInebilizumab 300 mg
RCP: Percentage of Participants Achieving Flare-free, Corticosteroid-free Complete Remission at Week 521540
SecondaryNumber of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) During the RCP

An adverse event (AE) referred to any untoward medical occurrence in a clinical study participant, regardless of a causal relationship with the study treatment. TEAEs included any event occurring after the participant received the study treatment. Clinically significant changes in vital signs, electrocardiograms, and laboratory tests recorded after treatment administration were documented as TEAEs. Serious AEs (SAEs) were untoward medical occurrences after the first dose, irrespective of a causal link to the study treatment, that led to death, were life-threatening, required hospitalization or its prolongation, caused significant disability, resulted in congenital anomalies, or were considered other medically important events. AEs were graded (Grade 3: severe; Grade 4: life-threatening; Grade 5: death) using the Common Terminology Criteria for Adverse Events \[CTCAE\]).

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) During the RCP
ParticipantsPlaceboInebilizumab 300 mg
TEAEs6666
SAEs612
Fatal TEAEs00
Grade ≥ 3 TEAEs812
SecondaryNumber of Participants Who Experienced TEAEs During the OLP

An AE referred to any untoward medical occurrence in a clinical study participant, regardless of a causal relationship with the study treatment. TEAEs included any event occurring after the participant received the study treatment. Clinically significant changes in vital signs, electrocardiograms, and laboratory tests recorded after treatment administration were documented as TEAEs. SAEs were untoward medical occurrences after the first dose, irrespective of a causal link to the study treatment, that led to death, were life-threatening, required hospitalization or its prolongation, caused significant disability, resulted in congenital anomalies, or were considered other medically important events. AEs were graded (Grade 3: severe; Grade 4: life-threatening; Grade 5: death) using the CTCAE).

Time frame:
From the first dose of investigational product in OLP to the end of OLP or cutoff date; median (min, max) duration was 51.6 (0.1, 108.3) weeks.

Results for this outcome have not been posted.

SecondaryRCP: Number of Participants With Anti-drug Antibodies (ADA) to Inebilizumab by Week 52

Incidence was the proportion of the participants with ADA positive post-baseline only or boosted their preexisting ADA (at least 4-fold over the baseline titer) during the study period. Baseline was defined as the last valid value on or before the first dose of RCP.

Time frame:
Baseline to Week 52
Reported as:
Count of participants · Participants
RCP: Number of Participants With Anti-drug Antibodies (ADA) to Inebilizumab by Week 52
ParticipantsPlaceboInebilizumab 300 mg
RCP: Number of Participants With Anti-drug Antibodies (ADA) to Inebilizumab by Week 5256
SecondaryRCP: Time to Initiation of First Treatment for New or Worsening Disease Activity Within the RCP

Time to initiation of the first treatment (medication or procedure) for new or worsening disease activity, as determined by the investigator, within the RCP, was measured from day 1 (dosing) to the date the first treatment was administered. It Included any treatment initiated by the investigator for disease activity, regardless of the AC determination of flare. KM method was used to estimate the median time to the initiation of first treatment or worsening of disease activity, and 95% CI.

Time frame:
Week 52
Reported as:
Median · Days
RCP: Time to Initiation of First Treatment for New or Worsening Disease Activity Within the RCP
DaysPlaceboInebilizumab 300 mg
RCP: Time to Initiation of First Treatment for New or Worsening Disease Activity Within the RCP237.0 (143.0 to 310.0)NA (371.0 to NA)
Statistical analysis
  • Placebo vs Inebilizumab 300 mg · Hazard ratio (hr): 0.12 · 95% CI 0.05 to 0.26Inebilizumab vs placebo
SecondaryRCP: Annualized Flare Rate for AC-Determined IgG4-RD Flares at Week 52

The annualized flare rate for AC-determined IgG4-RD flares, whether or not treated, during the RCP was calculated by dividing the total number of AC-determined flares by the total time at risk (in years) for all participants. This measure reflected the frequency of IgG4-RD flares, irrespective of treatment, per participant per year during the study period.

Time frame:
Week 52
Reported as:
Number · Flares per participant per year
RCP: Annualized Flare Rate for AC-Determined IgG4-RD Flares at Week 52
Flares per participant per yearPlaceboInebilizumab 300 mg
RCP: Annualized Flare Rate for AC-Determined IgG4-RD Flares at Week 520.75 (0.57 to 0.99)0.16 (0.09 to 0.29)
SecondaryRCP: Cumulative Glucocorticoid (GC) Use for IgG4-RD Disease Control by Week 52

GC use was calculated as the cumulative glucocorticoid dose (in milligrams) taken for the purpose of IgG4-RD disease control during the RCP. This measure accounted for all GC treatments administered to participants to manage disease activity throughout the study period.

Time frame:
Week 52
Reported as:
Mean · mg
RCP: Cumulative Glucocorticoid (GC) Use for IgG4-RD Disease Control by Week 52
mgPlaceboInebilizumab 300 mg
RCP: Cumulative Glucocorticoid (GC) Use for IgG4-RD Disease Control by Week 521384.53 ± 1723.26118.25 ± 438.97

Adverse events

Collected over For RCP mortality reporting: from randomization to the end of RCP; median (min, max) was 54.1 (2.1, 65.1) weeks. For RCP AE reporting: from Day 1 to the end of RCP or cutoff date; median (min, max) was 54.1 (2.1, 65.1) weeks. For OLP mortality and AE reporting: from the 1st dose of IP in OLP to the end of OLP or cutoff date; median (min, max) was 51.6 (0.1, 108.3) weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RCP: Placebo0/67 (0%)6/67 (9%)49/67 (73.1%)
RCP: Inebilizumab 300 mg0/68 (0%)12/68 (17.6%)54/68 (79.4%)
OLP: Inebilizumab 300 mg0/90 (0%)14/90 (15.6%)51/90 (56.7%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventRCP: PlaceboRCP: Inebilizumab 300 mgOLP: Inebilizumab 300 mg
PneumoniaInfections and infestations0/670/682/90
Coronary artery stenosisCardiac disorders1/670/680/90
Hepatic function abnormalHepatobiliary disorders1/670/680/90
Diabetes mellitusMetabolism and nutrition disorders1/670/681/90
Acute kidney injuryRenal and urinary disorders1/670/680/90
EpistaxisRespiratory, thoracic and mediastinal disorders1/670/680/90
Sinus disorderRespiratory, thoracic and mediastinal disorders1/670/680/90
Anaphylactic reactionImmune system disorders0/671/680/90
AppendicitisInfections and infestations0/671/680/90
COVID-19Infections and infestations0/671/680/90
Most frequent other events
Showing 10 of 30
Most frequent other events
EventRCP: PlaceboRCP: Inebilizumab 300 mgOLP: Inebilizumab 300 mg
COVID-19Infections and infestations13/6715/6819/90
LymphopeniaBlood and lymphatic system disorders6/6711/681/90
DiarrhoeaGastrointestinal disorders9/673/682/90
AstheniaGeneral disorders8/672/681/90
Upper respiratory tract infectionInfections and infestations8/674/6810/90
Urinary tract infectionInfections and infestations4/678/683/90
Abdominal painGastrointestinal disorders7/674/683/90
ArthralgiaMusculoskeletal and connective tissue disorders7/674/683/90
HeadacheNervous system disorders7/676/683/90
PruritusSkin and subcutaneous tissue disorders6/673/681/90

Baseline characteristics

Full Analysis Set: all participants who received any dose of investigational product during the RCP.

Age, Continuous
Age, Continuous(Years)PlaceboInebilizumab 300 mgTotal
Mean58.2 ± 12.258.2 ± 11.558.2 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboInebilizumab 300 mgTotal
Female182947
Male493988
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboInebilizumab 300 mgTotal
Hispanic or Latino8816
Not Hispanic or Latino5356109
Unknown or Not Reported6410
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboInebilizumab 300 mgTotal
American Indian or Alaska Native022
Asian253863
Black or African American101
Native Hawaiian or Other Pacific Islander011
White322153
Other224
Unknown101
Not Reported6410
08

Study locations

72 sites
  • Viela Bio Investigative Site
    Palo Alto, California 94305, United States
  • Viela Bio Investigative Site
    Atlanta, Georgia 30322, United States
  • Viela Bio Investigative Site
    Baltimore, Maryland 21287, United States
  • Viela Bio Investigative Site
    Boston, Massachusetts 02114, United States
  • Viela Bio Investigative Site
    Buenos Aires, Argentina
  • Viela Bio Investigative Site
    Mendoza, Argentina
  • Viela Bio Investigative Site
    Auchenflower, Queensland, Australia
  • Viela Bio Investigative Site
    Adelaide, South Australia, Australia
  • Viela Bio Investigative Site
    Fitzroy, Australia
  • Viela Bio Investigative Site
    Sherbrooke, Canada
  • Viela Bio Investigative Site 1
    Toronto, Canada
  • Viela Bio Investigative Site 2
    Toronto, Canada
  • Viela Bio Investigative Site
    Hohhot, Inner Mongolia, China
  • Viela Bio Investigative Site 1
    Beijing, China
  • Viela Bio Investigative Site 2
    Beijing, China
  • Viela Bio Investigative Site 3
    Beijing, China
  • Viela Bio Investigative Site 4
    Beijing, China
  • Viela Bio Investigative Site 5
    Beijing, China
  • Viela Bio Investigative Site
    Guandong, China
  • Viela Bio Investigative Site
    Shang’ai, China
  • Viela Bio Investigative Site
    Shenyang, China
  • Viela Bio Investigative Site
    Wuhan, China
  • Viela Bio Investigative Site
    Clichy, France
  • Viela Bio Investigative Site
    Lille, France
  • Viela Bio Investigative Site
    Marseille, France
  • Viela Bio Investigative Site
    Nantes, France
  • Viela Bio Investigative Site
    Pessac, France
  • Viela Bio Investigative Site
    Berlin, Germany
  • Viela Bio Investigative Site
    Lübeck, Germany
  • Viela Bio Investigative Site
    München, Germany
  • Viela Bio Investigative Site
    Hong Kong, Hong Kong
  • Viela Bio Investigative Site
    Debrecen, Hungary
  • Viela Bio Investigative Site
    Szeged, Hungary
  • Viela Bio Investigative Site
    Bangalore, India
  • Viela Bio Investigative Site
    Cork, Ireland
  • Viela Bio Investigative Site
    Kfar Saba, Israel
  • Viela Bio Investigative Site
    Petah Tikva, Israel
  • Viela Bio Investigative Site
    Tel Aviv, Israel
  • Viela Bio Investigative Site
    Tel Litwinsky, Israel
  • Viela Bio Investigative Site
    Florence, Italy
  • Viela Bio Investigative Site
    Milan, Italy
  • Viela Bio Investigative Site
    Pisa, Italy
  • Viela Bio Investigative Site
    Reggio Emilia, Italy
  • Viela Bio Investigative Site
    Torino, Italy
  • Viela Bio Investigative Site
    Verona, Italy
  • Viela Bio Investigative Site
    Fukuoka, Japan
  • Viela Bio Investigative Site
    Hokkaido, Japan
  • Viela Bio Investigative Site
    Hyōgo, Japan
  • Viela Bio Investigative Site
    Ishikawa, Japan
  • Viela Bio Investigative Site
    Kyoto, Japan
  • Viela Bio Investigative Site
    Niigata, Japan
  • Viela Bio Investigative Site 2
    Osaka, Japan
  • Viela Bio Investigative Site
    Osaka, Japan
  • Viela Bio Investigative Site
    Tokyo, Japan
  • Viela Bio Investigative Site
    Toyama, Japan
  • Viela Bio Investigative Siite
    Tlalpan, Mexico
  • Viela Bio Investigative Site
    Amsterdam, Netherlands
  • Viela Bio Investigative Site
    Rotterdam, Netherlands
  • Viela Bio Investigative Site
    Warsaw, Poland
  • Viela Bio Investigative Site
    Wroclaw, Poland
  • Viela Bio Investigative Site 2
    Barcelona, Spain
  • Viela Bio Investigative Site
    Barcelona, Spain
  • Viela Bio Investigative Site
    Madrid, Spain
  • Viela Bio Investigative Site
    Valencia, Spain
  • Viela Bio Investigative Site
    Gothenburg, Sweden
  • Viela Bio Investigative Site
    Stockholm, Sweden
  • Viela Bio Investigative Site
    Ankara, Turkey (Türkiye)
  • Viela Bio Investigative Site
    Istanbul, Turkey (Türkiye)
  • Viela Bio Investigative Site
    Leeds, United Kingdom
  • Viela Bio Investigative Site
    London, United Kingdom
  • Viela Bio Investigative Site
    Newcastle, United Kingdom
  • Viela Bio Investigative Site
    Oxford, United Kingdom
09

References and documents

Publications

  • Tanaka Y, Umehara H, Sato H, Uchima K, Kouji K, Okazaki K. Inebilizumab treatment in Japanese patients with IgG4-related disease: a subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 trial (MITIGATE). Mod Rheumatol. 2026 Mar 6:roag020. doi: 10.1093/mr/roag020. Online ahead of print. PubMed 41786624 ↗
  • Stone JH, Khosroshahi A, Zhang W, Della Torre E, Okazaki K, Tanaka Y, Lohr JM, Schleinitz N, Dong L, Umehara H, Lanzillotta M, Wallace ZS, Ebbo M, Webster GJ, Martinez Valle F, Nayar MK, Perugino CA, Rebours V, Dong X, Wu Y, Li Q, Rampal N, Cimbora D, Culver EL; MITIGATE Trial Investigators. Inebilizumab for Treatment of IgG4-Related Disease. N Engl J Med. 2025 Mar 27;392(12):1168-1177. doi: 10.1056/NEJMoa2409712. Epub 2024 Nov 14. PubMed 39541094 ↗
  • Perugino C, Culver EL, Khosroshahi A, Zhang W, Della-Torre E, Okazaki K, Tanaka Y, Lohr M, Schleinitz N, Falloon J, She D, Cimbora D, Stone JH. Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial. Rheumatol Ther. 2023 Dec;10(6):1795-1808. doi: 10.1007/s40744-023-00593-7. Epub 2023 Oct 4. PubMed 37792260 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Apr 2024, 40 months.

Results were first posted in Jun 2025, 1 year 2 months after primary completion. A results delay was requested in Mar 2025.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2020
First posted
Sep 7, 2020
StartActual
Dec 4, 2020
Primary completionActual
Apr 9, 2024
CompletionEst.
Oct 31, 2028
Results delay requested
Mar 31, 2025
Results first posted
Jun 25, 2025
Last update
Dec 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04540497
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Sep 7, 2020
Start date
Dec 4, 2020
Primary completion
Apr 9, 2024
Completion
Oct 31, 2028 (estimated)
Results posted
Jun 25, 2025
Last update
Dec 11, 2025

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inebilizumab

Start the discussion